NCT05331105View on ClinicalTrials.gov

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

October 30, 2025

Study Completion Date

October 31, 2028

Conditions
Neurofibromatosis 1Plexiform Neurofibromas
Interventions
DRUG

HL-085

"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."

Trial Locations (1)

200011

RECRUITING

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Kechow Pharma, Inc.

INDUSTRY

NCT05331105 - HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | Biotech Hunter | Biotech Hunter